Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Matt Poynton"'
2
Akademický článek
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
Autor: Faouzi Djebbari, Matt Poynton, Gina Sangha, Laura Anderson, Rebecca Maddams, Toby A. Eyre, Grant Vallance, Supratik Basu, Karthik Ramasamy
Publikováno v: Hematology, Vol 27, Iss 1, Pp 204-207 (2022)
Objectives: Daratumumab is the first anti-CD38 monoclonal antibody (Mab) used to treat myeloma in the newly diagnosed setting and in the relapsed setting. Isatuximab, another Mab targeting a specific epitope on the CD38 receptor, was recently approve
Externí odkaz: https://doaj.org/article/3808b0f54f8a4f84b3878e04294084d3
Zobrazit plný text záznamu
3
Akademický článek
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
Autor: Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Firas Al-Kaisi, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Ceri Bygrave, Supratik Basu, Karthik Ramasamy
Publikováno v: HemaSphere, Vol 6, Iss 6, p e738 (2022)
Real-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma patients have not been reported. In this UK-wide retrospective study, IsaPomDex outcomes were evaluated acro
Externí odkaz: https://doaj.org/article/b6d57c93eb6a43d19c387a4439f8466e
Zobrazit plný text záznamu
7
Akademický článek
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Autor: Djebbari, Faouzi1 (AUTHOR) faouzi.djebbari@ouh.nhs.uk, Rampotas, Alexandros1,2 (AUTHOR), Vallance, Grant1 (AUTHOR), Panitsas, Fotios3 (AUTHOR), Basker, Nanda4 (AUTHOR), Sangha, Gina5 (AUTHOR), Salhan, Beena6,7,8,9 (AUTHOR), Karim, Farheen9,10 (AUTHOR), Firas, Al-Kaisi11,12 (AUTHOR), Gudger, Amy9,13,14 (AUTHOR), Ngu, Loretta15 (AUTHOR), Poynton, Matt16 (AUTHOR), Lam, Ho Pui Jeff17 (AUTHOR), Morgan, Lowri18 (AUTHOR), Yang, Laura19 (AUTHOR), Young, Jennifer20 (AUTHOR), Walker, Mairi21 (AUTHOR), Tsagkaraki, Ismini22 (AUTHOR), Anderson, Laura23 (AUTHOR), Chauhan, Saleena Rani9,24 (AUTHOR)
Publikováno v: Hematology. Dec2022, Vol. 27 Issue 1, p691-699. 9p.
Zobrazit plný text záznamu
8
Akademický článek
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Autor: Djebbari, Faouzi1 (AUTHOR) Faouzi.Djebbari@ouh.nhs.uk, Poynton, Matt2 (AUTHOR), Sangha, Gina3 (AUTHOR), Anderson, Laura4 (AUTHOR), Maddams, Rebecca5 (AUTHOR), Eyre, Toby A.1 (AUTHOR), Vallance, Grant1 (AUTHOR), Basu, Supratik6,7,8 (AUTHOR), Ramasamy, Karthik1 (AUTHOR)
Publikováno v: Hematology. Dec2022, Vol. 27 Issue 1, p204-207. 4p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje